KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Expenditures (2017 - 2025)

Amneal Pharmaceuticals has reported Capital Expenditures over the past 9 years, most recently at $21.8 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $21.8 million for Q4 2025, up 43.67% from a year ago — trailing twelve months through Dec 2025 was $70.1 million (up 34.93% YoY), and the annual figure for FY2025 was $70.1 million, up 34.93%.
  • Capital Expenditures for Q4 2025 was $21.8 million at Amneal Pharmaceuticals, up from $12.3 million in the prior quarter.
  • Over the last five years, Capital Expenditures for AMRX hit a ceiling of $22.8 million in Q2 2025 and a floor of $5.0 million in Q2 2022.
  • Median Capital Expenditures over the past 5 years was $11.7 million (2021), compared with a mean of $13.0 million.
  • Biggest five-year swings in Capital Expenditures: plummeted 40.75% in 2021 and later skyrocketed 137.73% in 2023.
  • Amneal Pharmaceuticals' Capital Expenditures stood at $17.5 million in 2021, then plummeted by 34.47% to $11.5 million in 2022, then fell by 13.96% to $9.9 million in 2023, then surged by 53.62% to $15.2 million in 2024, then soared by 43.67% to $21.8 million in 2025.
  • The last three reported values for Capital Expenditures were $21.8 million (Q4 2025), $12.3 million (Q3 2025), and $22.8 million (Q2 2025) per Business Quant data.